The emerging class of GLP-1 receptor and GIP co-agonist medications, including tirzepatide, semaglutide, and the recently introduced retatrutide, offer promising advances in diabetes management . Although https://ghkcucopperpeptide209842.blogfrogs.com/959464/retatrutide-the-comparative-look